Date: Monday, May 3, 2021
Time: 1:00 PM EDT

IVI launched the Major Depressive Disorder (MDD) initiative to build a flexible, open-source, and patient-centric model that will help inform the decision needs of multiple stakeholders in the health care system.

According to the National Alliance on Mental Illness, over 19 million adults had at least one MDD episode in the past year; the COVID-19 pandemic has only exacerbated the unmet need for depression treatment. Conventional cost-effectiveness models for assessing the value of MDD treatments typically do not prioritize factors and outcomes important to patients.

This webinar covered the major points of the new model scope for the MDD initiative, and addressed the importance of a patient-centric model for MDD. Via a public comment period from April 12th to May 14th, stakeholders were invited to provide recommendations on the most important factors to build into the model.

Rick Chapman, PhD (Moderator)
Rick Chapman, PhD (Moderator)Innovation and Value Initiative
Jessica Kennedy
Jessica KennedyMental Health America
In her role as Chief of Staff at Mental Health America, Ms. Kennedy focuses on screening, workplace mental health, public education, digital marketing, mental health policy, and program management. She launched the organization’s online screening program in 2014, now the largest database of mental health screens worldwide.
Mohannad (Ned) Kusti, MD, MPH
Mohannad (Ned) Kusti, MD, MPHPivot Onsite-Innovations
A global physician executive and healthcare consultant, Dr. Kusti has unique expertise and experience related to corporate healthcare benefits. He is consulting for numerous employers in COVID-19 corporate management. Dr. Kusti also teaches occupational and environmental health sciences at West Virginia University.
Richard Xie, PhD
Richard Xie, PhDInnovation and Value Initiative
A health economist and HEOR Manager at the Innovation and Value Initiative, Dr. Xie has played a lead role in developing the IVI-Major Depressive Disorder Model Scope. He has a long track record of conducting HEOR studies to inform health policy design and valuation of pharmaceutical therapies.

View Recorded Webinar


View Presentation Slide Deck